Labcorp Holdings (NYSE:LH) announced a variety of business advances, including partnerships, earnings reports, and executive stock sales. The clinical lab company missed Q1 2025 estimates with an EPS of $2.52 and revenue of $3.35 Billion.
Labcorp expanded its partnership with Frame to enhance fertility testing access, and acquired select assets of
BioReference Health's innovative oncology and related clinical testing services. Company heads such as CFO Glenn Eisenberg, CEO Adam Schechter and EVP Mark Schroeder offloaded significant shares, presumably after financial reviews. Despite these developments, analysts remain bullish on the company. For instance, Mizuho raised the price target from $264 to $274, indicating a potential upside of the holdings. Major acquisitions such as the assets of Invitae are expected to enhance the company's foothold in the clinical lab market. Furthermore, the company finalized its plans for a laboratory expansion in Japan and announced spin-off of Fortrea, marking significant developments in its global outreach. On the downside, it recently closed a newly acquired laboratory, leading to layoffs for 53 employees.
Laboratory Corporation of America Holdings LH News Analytics from Mon, 07 Feb 2022 08:00:00 GMT to Fri, 23 May 2025 21:45:14 GMT -
Rating 4
- Innovation 5
- Information -1
- Rumor 7
